1. Home
  2. NCEL vs CTXR Comparison

NCEL vs CTXR Comparison

Compare NCEL & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$2.59

Market Cap

20.7M

Sector

Health Care

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$1.06

Market Cap

19.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCEL
CTXR
Founded
2008
2007
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.7M
19.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCEL
CTXR
Price
$2.59
$1.06
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
90.9K
518.6K
Earning Date
12-01-2025
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.48
$0.65
52 Week High
$7.64
$5.95

Technical Indicators

Market Signals
Indicator
NCEL
CTXR
Relative Strength Index (RSI) N/A 42.84
Support Level N/A $1.01
Resistance Level N/A $1.20
Average True Range (ATR) 0.00 0.09
MACD 0.00 -0.01
Stochastic Oscillator 0.00 14.26

Price Performance

Historical Comparison
NCEL
CTXR

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: